

Inside the Issue: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The Phase II DORA trial is evaluating durvalumab in combination with which of the following agents as maintenance treatment after platinum-based chemotherapy for patients with metastatic triple-negative breast cancer?**
 - Datopotamab deruxtecan
 - Trastuzumab deruxtecan (T-DXd)
 - Olaparib**
 - Magrolimab
- 2. The prevalence of HER2-low (IHC1+/2+, FISH-negative) disease is higher in populations of patients with which subtype of breast cancer?**
 - Hormone receptor-negative
 - Hormone receptor-positive**
 - Prevalence is about the same in both groups
- 3. Which of the following proteins is targeted by datopotamab deruxtecan?**
 - CDH1
 - CHEK2
 - PALB2
 - TROP2**
- 4. The ongoing Phase III ASCENT-07 study is evaluating sacituzumab govitecan versus treatment of physician's choice in which of the following settings?**
 - As first-line therapy for ER-negative, HER2-positive metastatic breast cancer (mBC)
 - As first-line therapy for ER-positive, HER2-negative mBC**
 - As second-line therapy for ER-negative, HER2-positive mBC
 - As second-line therapy for ER-positive, HER2-negative mBC
- 5. Which of the following any-grade adverse events was most commonly reported by patients receiving T-DXd for previously treated HER2-low advanced breast cancer in the Phase III DESTINY-Breast04 trial?**
 - Hyperphosphatemia
 - Hand-foot syndrome
 - Nausea**
 - Confusion